COMPANY

PRESENTATION SimySkin Inc.

Where Money Meets Ideas

Cautionary Statement

The following document contains certain forward-looking statements and forward-looking information, which is based on hypothetical data, which includes current expectations, estimates, projections, assumptions and beliefs. By their nature, forward-looking statements and hypothetical data is subject to a number risks and uncertainties, because they relate to future events and

circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. The additional disclosure information regarding the forward-looking statements mythology, assumptions and risks is available. These forward-looking statements may be identified by words such as “believes”, “expects”, “anticipates”, “projects”, “projected”, “pro forma”, “intends”, “forecasted”, “forecast”, “assumed”, “should”, “continue”, “seeks”, “may”, “will", "estimates”, “estimated”, “future”, “could”, “probably” or similar words or expressions or by discuss ion of strategy, goals, plans, intentions or projections of revenues, earnings, segment performance, cash flows, contract awards, market size, industry trends, expenses and future financing. It is believed that the expectations reflected in the forward-looking statements and forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct, and such forward-looking statements and information should not be unduly relied upon, because the actual future results may differ materially from the plans, goals, and expectations set forth in such forward-looking statements. The forward-looking information and statements are only as of the date they are made. All subsequent written and oral forward-looking statements made are qualified by the cautionary statements in this section. There is no undertaking or assumption of any obligation to update or revise any of the included forward-looking statements or information, whether as a result of new information, changes in expectations or circumstances, future events or otherwise.

Confidentiality Statement

The information in this document is confidential to the person or entity to whom it is addressed and should not be disclosed to any other person or entity. It may not be reproduced in whole, or in part, nor may any of the information contained therein be di sclosed without the prior consent of the Company which is being featured in this document. A recipient may not solicit, directly or indirectly

(whether through an agent or otherwise) the participation of another institution or person without the prior approval of the directors of the Company which is being featured in this document. The contents of this document have not been independently verified and they do not purport to be comprehensive, or to contain all necessary information to make an investment decision. Except for obligations under Ontario securities law, no representation, warranty or undertaking, expressed or implied is or will be made or given and no responsibility or liability is or will be accepted by the company being featured in this document or by P2P Financial Inc., doing business as The OCMX, or by any of its directors, employees or advisors in relation to the accuracy or completeness of this document or any other written or oral information made available in connection with The OCMX. Any form of reproduction, dissemination, copying, disclosure, modification, distribution and or publication of this material is strictly prohibited.

Company Overview

SimySkin helps women naturally lessen the effects of time on their skin at each phase of their lives. We do this by developing, producing and selling targeted Vitamin B12 based products which prevent, maintain, and repair the integrity of the skin.

SimySkin Inc.

Competitive Advantages

SimySkin™ is a pioneer,

teaming up with a prominent oncologist to help determine

the effect of each ingredient

used in the formulation of the Company’s anti-aging

products.

The oncology approach is

combined with the principles of systems biology to develop

better formulations.

ONCOLOGY APPROACH SIGNATURE INGREDIENT

The Vitamin B12 is our

signature ingredient.

We have an intimate knowledge of how it works

best, which helps in the

formulation and the delivery method of our products based

on the principles of systems

biology.

INTELLECTUAL PROPERTY

SimySkin™ has an agreement

with Kyto IP to use its Vitamin B12 IP.

Kyto has assembled a

portfolio of 21 pending or

granted patents, related to B12 targeting technology and

filed for protection in USA,

Canada, Japan and Europe.

VALUE FOR MONEY

We combine the best of

French and American formulation and

manufacturing, are more

generous with active ingredients and offer great

value per ml size for the

sophisticated consumer.

Market Size

• The Global Skin Care markets – estimated at $111B, with the markets of US and Europe accounting for about $45B

• TAM (Total Available Market) – Skin care remains the key revenue driver in beauty with global sales exceeding US$111 billion in 2014

• SAM (Serviceable Available Market) - US and European skin care markets, primary targets for SimySkin ™, are estimated at $45B

• Depending on the source, the lowest estimate for the US Skin Market stands at about $12.5 B

TAM $111B

SAM $45B

Competitive Benchmarking

SimySkin™ products are competitively positioned in terms of number of active ingredients and price per ml of serum

FACE SERUMS COMPETITIVE BENCHMARKING*

Pri

ce p

er m

l ($)

Number of active ingredients (#)

SimySkin

Ole Henriksen

Phylosophy

Elizabeth Arden - Prevage

Dior

Skinceuticals

Estée Lauder Lancôme

L´occitane

Caudalie

Biotherm

Andrew Weil

Olay

L´oreal Clarins

Kiehl´s Andrew Weil

Andrew Weil

Product Key Components

INDEPENDENTLY TESTED

Serums with clinically proven results in 8 weeks. Show improvement in

skin elasticity, hydration, firmness and decrease deep wrinkles and redness

B12 SIGNATURE INGREDIENT

Know-How developed over 15 years of collaboration between Kyto IP, State University of New York and Dr. Uri Sagman, a Toronto oncologist

PLANT DERIVED INGREDIENTS

All the serums have active, unique and innovative plant derived ingredients that are targeted to each phase (Prevent – Maintain – Repair)

PARABEN FREE

Our products are paraben, sulfate, alcohol and soap free

AGE SPECIFIC SOLUTIONS

Serums are split in age groups, Phase I 18 to 25 (Prevent) Phase II 25 to 45 (Maintain) and Phase III 45+ (Repair)

Marketing/Growth Strategy

Product Strategy

• Develop one or two blockbuster products (serums) with patent which might be considered “medical” as opposed to “cosmetics”.

• The R&D cost for new products development plus legal and FDA filing costs will be important and this path will be pursued depending on the funds raised.

Retail Distribution

• Emphasis is on bricks and mortar as it remains the most efficient way to showcase the products since it allows consumers to test easily.

Promotion Strategy and Brand Building

• Part of the investment will be channeled into traditional and social media as Internet is a rapidly growing segment of consumer influence and will drive traffic to the stores.

Geography of Distribution

• The US is the largest market. Depending on funding, marketing efforts will start for EU. Other markets will be considered and the approach will mainly be through distributors, not direct marketing efforts.

Key Milestones

Nov 2012

Incorporation

Feb 2013 Decision to create first serum

as a test of quality + presentation

Feb 2014 Successful presentation of 3 Phases Eye Serum to Cannes (ECRM) international trade show. Decision to create a

compact line

Feb 2015 Launch PR

Mar 2015 Presentation of 15 SKU

compact line at 3 international trade shows: Vienna (ECRM), Bologna,

Frankfurt

May/June 2015 Launch marketing efforts

June/Dec 2015 Signing of first e-commerce

sites and launch e-store

Jan 2016 Negotiations with more than 26 active accounts,

some of them high-profile retail chains

Intellectual Property & Products

• Vitamin B12 – Property of Kyto IP Inc. and State University of New York.

Product Age Group Triple Advanced Face Serum

30ml 25 to 45

Advanced Essential Face Serum 30ml

45 +

Hydrating & Nourishing Face Moisturizer 50 ml

All

Gel Cleanser Anti-Aging For Her / Him 120 ml

All

Micro Exfoliating Toner 120 ml All

Soothing Toner 120 ml All

Exfoliating Scrub For Her / Him 90 ml

All

Ultra Fine Scrub 90 ml All

Deep Hydrating Mask For Her / Him 60 ml

All

Product Age Group

Phase I Eye Serum 30 ml 18 to 25

Phase II Eye Serum 30 ml 25 to 45

Phase III Eye Serum 30 ml 45 +

Nourishing Eye Cream 30 ml All

FACE SOLUTIONS EYE SOLUTIONS

Product Age Group

Intensive Lift Neck Serum 30 ml 25 to 45

Intensive Ultra Lift Neck Serum 30 ml

45 +

NECK SOLUTIONS

Use of Proceeds

Category Amount (M)

PR & Marketing – US, Canada, and EU $0.4 ̴ $0.8

Trade Shows & Events – Supports retail and online sales and distribution

$0.15 ̴ $0.35

New Product(s) - New serums (3) and new creams (3), of which two serums with patent protection. Subject to the amount of funding

$0.45 ̴ $1.7

Working Capital – Inventories on hand supporting distribution $0.55 ̴ $1.0

Staff – Full time COO Sales, e-commerce, and misc. staff $0.4 ̴ $0.9M

Total $1.95 ̴ $4.75

Management Team

Georges Benarroch, CEO & Founder Georges Benarroch has developed specialized expertise in corporate finance and investing as an investment banker for over 30 years. After obtaining multiple graduate and post-graduate degrees in law, political sciences and international relations from Universities in France and Canada, he began his banking career in Paris. He then established his own private investment banking firm in the USA and in Canada

For the past 3 decades, Georges Benarroch has been a successful financial intermediary and investor. He has created and managed institutional brokerage as well as wealth management firms. Today he operates through Comindus Finance.

Dr. Uri Sagman, M.D., FRCPC, Special Advisor and Scientific Research Dr. Sagman is a well-respected researcher who has received numerous awards and citations including the Young Investigator awards of the American Society of Clinical Oncology (ASCO) and the American Association of Cancer Research (AACR). Dr. Uri Sagman is a highly respected oncologist who has co-founded a nanomedicine company focused on the development of fullerene antioxidants for the treatment of Parkinson’s disease, Alzheimer’s disease and certain skin conditions related to aging and UV exposure.

Toronto Office TD Canada Trust Tower

161 Bay Street, 45th Floor

Toronto, ON M5J 2S1

1-866-209-6862